



BioPharmica Limited

30 November 2005

ASX Announcement Key Appointment of Managing Director

Biotechnology commercialization company BioPharmica Limited (**ASX: BPH**) is pleased to announce the appointment of Dr. Sam Gallagher as Managing Director of the company.

This is the third significant appointment made by BioPharmica and reflects the increasing progress of the project portfolio towards commercialization.

As a senior R&D scientist for Amersham Biosciences, and GE Healthcare, Dr. Gallagher brings her significant product development and international partnering experience relating to large pharmaceutical and biotech companies to the BioPharmica Board. Headquartered in the United Kingdom, GE Healthcare is a \$15 billion unit of General Electric Company.

Dr Gallagher was involved in the development and launch of multi million dollar biomedical products produced by Amersham Biosciences and GE healthcare from conception to application, validation and sale. This was achieved whilst maintaining an active interest in new and untried science and technology by personally project managing multi million dollar ideas evaluation and functional genomics projects. Dr Gallagher has worked collaboratively with leading international scientists across Europe, America and Canada.

Dr. Gallagher gained her PhD from The University of Wales, College Cardiff, this followed on from her joint honours degree in Biochemistry and Zoology from the same institution. Her PhD was sponsored by, the then ICI, and involved the development of the cancer treatment based on small peptide hormones. Dr. Gallagher, garnered strong international experience, during a series of post doctoral fellowships in lung toxicology, imaging, particulate and cell based analysis and validation fields.

Dr Gallagher moved to Belgium to coordinate the management of a BioMed collaboration bringing together scientists across 17 East and Western European countries to standardize the isolation of lung cells across species and research groups. Dr Gallagher won an MRC fellowship for the effects of particulate pollutants on the lungs and was a committee member and Editor for the British Association of Lung Research.

"Dr Gallagher is a seasoned commercialization specialist that has focused on biotech and healthcare throughout most of her professional career. BioPharmica will greatly benefit from her experience," said David Breeze, Chairman BioPharmica Limited.

2, Boans Lane, East Perth, Western Australia, 6004
Telephone + 61 (08) 9244 9631 Facsimile+ 61 (08) 9244 9782
Email admin@biopharmica.com.au
Internet www.biopharmica.com.au



BioPharmica Limited

Dr Gallagher said "There has been a major shift by international companies towards tailoring personalized treatments to individual patients. BioPharmica has a unique opportunity to move forward in the areas of translational medicine and there are aspects to the project portfolio that will be very exciting to develop and take to the market."

"Forming partnerships is a key value driver in the Biotechnology industry. This is even more important in the Australian biotech industry, which continues to expand but is still small in global terms. Alliances with larger multinationals are likely to be the most successful strategy to penetrate international markets."

"Each of the investment areas of BioPharmica's portfolio are independent having been developed from single strategic ideas, however, with the initial phase of development near completion the projects are diversifying with multi-faceted potential, attracting international interest, collaboration and partnership opportunities."

The BioPharmica portfolio contains projects involved in medical devices, diagnostic arrays, component manufacture and biomarkers linked to therapy.

Company and Project Portfolio

BioPharmica is a company dedicated to the ideals of Personalized Medicine through the applied development of discoveries made from fundamental research. Globally, healthcare has moved away from mass produced solutions to biotechnology programmes designed to address the issues of the individual.

Currently, BioPharmica is working to commercialise a portfolio of Australian biomedical research projects with leading universities, medical institutes and hospitals targeting large global markets. It is recognized world wide that Australian research and invention is as rich and diverse as its natural resources.

BioPharmica is committed to facilitating the development of biomedical research in order to compete internationally, producing marketable intellectual property and a movement to the development path within a much reduced time frame.

The diverse portfolio of projects undergoing pre-clinical and clinical development in the production of diagnostic arrays, nanotechnology, biomarkers and therapeutics are designed around state of the art technology, specifically to deliver validated, individually tailored healthcare solutions.

The project portfolio, driven by BioPharmica Ltd., is diverse and robust, each adding to the paradigm of personalized medicine. The projects have developed from single focal base into networks of applications and advancements. The portfolio has attracted interest internationally, reinforcing the knowledge that Australia is producing global cutting edge science.